Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts

Area of Science:

• Neuro-oncology
• Cancer Biology
• Immunotherapy

Background:

• Glioblastoma is the most common malignant brain tumor, presenting with aggressive characteristics and high recurrence rates.
• Current standard treatments (surgery, radiation, temozolomide) offer limited long-term survival, with only 15-20% of patients surviving 5 years.
• Advances in understanding glioblastoma's molecular pathology have paved the way for innovative therapeutic strategies.

Purpose of the Study:

• To review recent advances in targeted therapies for glioblastoma.
• To discuss the emerging role of immunotherapy in glioblastoma management.
• To highlight improvements in clinical management strategies for glioblastoma patients.

Main Methods:

• Literature review of recent studies on glioblastoma treatments.
• Analysis of clinical trial data for novel targeted therapies and immunotherapies.
• Synthesis of information on improved patient management protocols.

Main Results:

• Novel targeted therapies are being developed for newly diagnosed and recurrent glioblastomas.
• Immunotherapy shows promise with acceptable safety and tolerability in recurrent glioblastoma.
• Clinical management, including supportive care and centralization, has seen significant improvements.

Conclusions:

• Targeted therapies and immunotherapy represent promising avenues for glioblastoma treatment.
• Further research and clinical trials are crucial to establish durable survival benefits.
• Integrated approaches combining novel therapies with improved clinical management are essential for better patient outcomes.